Van Andel Receives FDA OK to Test Feasibility of Genomically Guided Pediatric Cancer Treatment
June 01, 2011
Van Andel Receives FDA OK to Test Feasibility of Genomically Guided Pediatric Cancer Treatment
The Neuroblastoma and Medulloblastoma Translational Research Consortium will conduct a 14-patient trial in which it will try to pinpoint treatments that best suit individual participants based on their gene expression profiles.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Consortium Launches Genomic-Based Clinical Trial for Pediatric Neuroblastoma
May 31, 2011 / Clinical Sequencing News - Outbreak Tracking and Monitoring Emerges as Key Application for NGS in 2012
December 19, 2012 / Clinical Sequencing News - FDA Official Discusses Issues with Regulating NGS Dx Tests
June 20, 2012 / Clinical Sequencing News - Incidental Findings from Sequencing Studies Should be Returned, Say Genetics Specialists
March 21, 2012 / Clinical Sequencing News - Q&A: Matt Posard on Illumina's Clinically Focused Business Unit
March 14, 2012 / Clinical Sequencing News